Cargando…

Two-stage hepatectomy after autologous CD133+ stem cells administration: a case report

Liver resection is the mainstay of treatment for patients with primary and metastatic liver tumors. However, a large majority of patients present for initial medical evaluation with primary and metastatic liver tumors when their cancer is unresectable. Several trials have been undertaken to identify...

Descripción completa

Detalles Bibliográficos
Autores principales: Franchi, Eloisa, Canepa, Maria C, Peloso, Andrea, Barbieri, Letizia, Briani, Laura, Panyor, Gabor, Dionigi, Paolo, Maestri, Marcello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751571/
https://www.ncbi.nlm.nih.gov/pubmed/23941680
http://dx.doi.org/10.1186/1477-7819-11-192
_version_ 1782281626564165632
author Franchi, Eloisa
Canepa, Maria C
Peloso, Andrea
Barbieri, Letizia
Briani, Laura
Panyor, Gabor
Dionigi, Paolo
Maestri, Marcello
author_facet Franchi, Eloisa
Canepa, Maria C
Peloso, Andrea
Barbieri, Letizia
Briani, Laura
Panyor, Gabor
Dionigi, Paolo
Maestri, Marcello
author_sort Franchi, Eloisa
collection PubMed
description Liver resection is the mainstay of treatment for patients with primary and metastatic liver tumors. However, a large majority of patients present for initial medical evaluation with primary and metastatic liver tumors when their cancer is unresectable. Several trials have been undertaken to identify alternative treatments and complementary therapies. In the near future, the field of liver surgery will aim to increase the number of patients that can benefit from resection, since radical removal of the tumor currently provides the sole chance of cure. This paper reports the case of a patient with an advanced colonic cancer in the era of stem cell therapyIn 2011, a 57 years old white Caucasian man with a previous history of non-Hodgkin lymphoma (NHL) was diagnosed with colon cancer and bilobar liver metastases. Following neoadjuvant therapy, the patient was enrolled in a protocol of stem cell administration for liver regeneration. Surgery was initially performed on the primary cancer and left liver lobe. An extended right lobectomy to S1 was then performed after a portal vein embolization (PVE) and stem cell stimulation of the remaining liver. The postoperative course was uneventful and the patient was free of disease after 12 months. Extreme liver resection can provide a safer option and a chance of cure to otherwise unresectable patients when liver regeneration is boosted by PVE and stem cell administration.
format Online
Article
Text
id pubmed-3751571
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-37515712013-08-24 Two-stage hepatectomy after autologous CD133+ stem cells administration: a case report Franchi, Eloisa Canepa, Maria C Peloso, Andrea Barbieri, Letizia Briani, Laura Panyor, Gabor Dionigi, Paolo Maestri, Marcello World J Surg Oncol Case Report Liver resection is the mainstay of treatment for patients with primary and metastatic liver tumors. However, a large majority of patients present for initial medical evaluation with primary and metastatic liver tumors when their cancer is unresectable. Several trials have been undertaken to identify alternative treatments and complementary therapies. In the near future, the field of liver surgery will aim to increase the number of patients that can benefit from resection, since radical removal of the tumor currently provides the sole chance of cure. This paper reports the case of a patient with an advanced colonic cancer in the era of stem cell therapyIn 2011, a 57 years old white Caucasian man with a previous history of non-Hodgkin lymphoma (NHL) was diagnosed with colon cancer and bilobar liver metastases. Following neoadjuvant therapy, the patient was enrolled in a protocol of stem cell administration for liver regeneration. Surgery was initially performed on the primary cancer and left liver lobe. An extended right lobectomy to S1 was then performed after a portal vein embolization (PVE) and stem cell stimulation of the remaining liver. The postoperative course was uneventful and the patient was free of disease after 12 months. Extreme liver resection can provide a safer option and a chance of cure to otherwise unresectable patients when liver regeneration is boosted by PVE and stem cell administration. BioMed Central 2013-08-13 /pmc/articles/PMC3751571/ /pubmed/23941680 http://dx.doi.org/10.1186/1477-7819-11-192 Text en Copyright ©2013 Franchi et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Franchi, Eloisa
Canepa, Maria C
Peloso, Andrea
Barbieri, Letizia
Briani, Laura
Panyor, Gabor
Dionigi, Paolo
Maestri, Marcello
Two-stage hepatectomy after autologous CD133+ stem cells administration: a case report
title Two-stage hepatectomy after autologous CD133+ stem cells administration: a case report
title_full Two-stage hepatectomy after autologous CD133+ stem cells administration: a case report
title_fullStr Two-stage hepatectomy after autologous CD133+ stem cells administration: a case report
title_full_unstemmed Two-stage hepatectomy after autologous CD133+ stem cells administration: a case report
title_short Two-stage hepatectomy after autologous CD133+ stem cells administration: a case report
title_sort two-stage hepatectomy after autologous cd133+ stem cells administration: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751571/
https://www.ncbi.nlm.nih.gov/pubmed/23941680
http://dx.doi.org/10.1186/1477-7819-11-192
work_keys_str_mv AT franchieloisa twostagehepatectomyafterautologouscd133stemcellsadministrationacasereport
AT canepamariac twostagehepatectomyafterautologouscd133stemcellsadministrationacasereport
AT pelosoandrea twostagehepatectomyafterautologouscd133stemcellsadministrationacasereport
AT barbieriletizia twostagehepatectomyafterautologouscd133stemcellsadministrationacasereport
AT brianilaura twostagehepatectomyafterautologouscd133stemcellsadministrationacasereport
AT panyorgabor twostagehepatectomyafterautologouscd133stemcellsadministrationacasereport
AT dionigipaolo twostagehepatectomyafterautologouscd133stemcellsadministrationacasereport
AT maestrimarcello twostagehepatectomyafterautologouscd133stemcellsadministrationacasereport